[{"orgOrder":0,"company":"Biocon","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biocon \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Biocon \/ Zentiva"},{"orgOrder":0,"company":"Biocon","sponsor":"Juno Pharmaceuticals Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Juno Pharmaceuticals Pty Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Juno Pharmaceuticals Pty Ltd"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"4Moving Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Zentiva","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Zentiva","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Zentiva"},{"orgOrder":0,"company":"4P-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Liraglutide","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4P-Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"4P-Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"4P-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Medix","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Liraglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Medix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medix \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Medix \/ Biocon"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Adalvo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adalvo \/ Not Applicable"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"4Moving Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"4Moving Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"4Moving Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexaria Bioscience \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Liraglutide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Oral DehydraTECH-technology processed liraglutide (GLP-1 agonist) is being investigated for obesity in comparison with Rybelsus (semaglutide).

                          Brand Name : DehydraTECH-liraglutide

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          November 20, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Oral DehydraTECH-technology processed semaglutide and liraglutide (GLP-1 agonist) is being investigated for obesity.

                          Brand Name : DehydraTECH-liraglutide

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          October 24, 2024

                          Lead Product(s) : Liraglutide,Semaglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : DehydraTECH-Liraglutide (liraglutide) is a DehydraTECH-processed GLP-1 receptor agonist, which is being evaluated for the treatment of diabetes and weight loss.

                          Brand Name : DehydraTECH-liraglutide

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          October 22, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Saxenda is a GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity being investigated for chronic weight management in 6-12 years old patients.

                          Brand Name : Saxenda

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          September 10, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : DehydraTECH-Liraglutide (liraglutide) is a DehydraTECH-processed GLP-1 receptor agonist, which is being evaluated for the treatment of diabetes and weight loss.

                          Brand Name : DehydraTECH-Liraglutide

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          August 22, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is investigated for the treatment of patients with mild alzheimer's disease.

                          Brand Name : Victoza

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          July 29, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Victoza-Generic (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.

                          Brand Name : Victoza-Generic

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          June 24, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Victoza-Generic (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.

                          Brand Name : Victoza-Generic

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          June 13, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : 4P004 (intraarticular liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with knee osteoarthritis.

                          Brand Name : 4P004

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          June 10, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Under the agreement, Biocon will obtain regulatory approval and manufacture Saxenda (liraglutide) for chronic weight management, while Medix will commercialize it in Mexico.

                          Brand Name : Saxenda-Generic

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          May 13, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved

                          Sponsor : Biocon

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank